CN110381986B - 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽 - Google Patents

用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽 Download PDF

Info

Publication number
CN110381986B
CN110381986B CN201780069945.0A CN201780069945A CN110381986B CN 110381986 B CN110381986 B CN 110381986B CN 201780069945 A CN201780069945 A CN 201780069945A CN 110381986 B CN110381986 B CN 110381986B
Authority
CN
China
Prior art keywords
fviii
administered
recombinant polypeptide
polypeptide
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780069945.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110381986A (zh
Inventor
S·佩斯特尔
E·拉凯
T·韦默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
Original Assignee
CSL Behring Recombinant Facility AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Recombinant Facility AG filed Critical CSL Behring Recombinant Facility AG
Publication of CN110381986A publication Critical patent/CN110381986A/zh
Application granted granted Critical
Publication of CN110381986B publication Critical patent/CN110381986B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780069945.0A 2016-11-11 2017-11-10 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽 Active CN110381986B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16198497.6 2016-11-11
EP16198497 2016-11-11
PCT/EP2017/078840 WO2018087271A1 (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Publications (2)

Publication Number Publication Date
CN110381986A CN110381986A (zh) 2019-10-25
CN110381986B true CN110381986B (zh) 2023-08-18

Family

ID=57389201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069945.0A Active CN110381986B (zh) 2016-11-11 2017-11-10 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽

Country Status (12)

Country Link
US (1) US11890327B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538134B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020504082A (cg-RX-API-DMAC7.html)
KR (1) KR20190073576A (cg-RX-API-DMAC7.html)
CN (1) CN110381986B (cg-RX-API-DMAC7.html)
AU (1) AU2017358865A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043397A1 (cg-RX-API-DMAC7.html)
DK (1) DK3538134T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908008T3 (cg-RX-API-DMAC7.html)
SG (2) SG10201912768YA (cg-RX-API-DMAC7.html)
TW (1) TW201828974A (cg-RX-API-DMAC7.html)
WO (1) WO2018087271A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
JP7780341B2 (ja) * 2019-07-04 2025-12-04 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
KR102647642B1 (ko) * 2021-05-04 2024-03-15 (주)케어젠 혈액 응고 활성을 갖는 펩타이드와 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228613B1 (en) * 1996-03-15 2001-05-08 Baxter Aktiengesellschaft Stable factor VIII/von Willebrand factor complex
CN104411716A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S（股份有限公司） 适用于治疗血友病的化合物
CN104411323A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S（股份有限公司） 适用于治疗血友病的药物组合物
CN105163751A (zh) * 2013-04-22 2015-12-16 杰特有限公司 复合物
CN105452289A (zh) * 2013-06-12 2016-03-30 诺和诺德股份有限公司 适用于治疗血友病的化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
ES2343681T3 (es) 2002-04-29 2010-08-06 Stichting Sanquin Bloedvoorziening Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
WO2006108590A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
KR101641899B1 (ko) 2006-06-14 2016-08-01 체에스엘 베링 게엠베하 혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
KR20100019999A (ko) 2007-06-13 2010-02-19 체에스엘 베링 게엠베하 출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
SG10201701037WA (en) 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
ES2895798T3 (es) 2014-06-06 2022-02-22 Octapharma Ag Preparación que comprende péptidos del factor VIII y del factor Von Willebrand
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228613B1 (en) * 1996-03-15 2001-05-08 Baxter Aktiengesellschaft Stable factor VIII/von Willebrand factor complex
CN104411716A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S（股份有限公司） 适用于治疗血友病的化合物
CN104411323A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S（股份有限公司） 适用于治疗血友病的药物组合物
CN105163751A (zh) * 2013-04-22 2015-12-16 杰特有限公司 复合物
CN105452289A (zh) * 2013-06-12 2016-03-30 诺和诺德股份有限公司 适用于治疗血友病的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FVIII stabilization: VWF D′D3 will do;L.L. SWYSTUN等;《Blood》;20140717;第124卷(第3期);第313页摘要，第314页的图、第2栏第2段 *

Also Published As

Publication number Publication date
EP3538134A1 (en) 2019-09-18
ES2908008T3 (es) 2022-04-27
DK3538134T3 (da) 2022-02-07
WO2018087271A1 (en) 2018-05-17
US11890327B2 (en) 2024-02-06
TW201828974A (zh) 2018-08-16
SG11201903954WA (en) 2019-05-30
SG10201912768YA (en) 2020-02-27
KR20190073576A (ko) 2019-06-26
US20210268071A1 (en) 2021-09-02
AU2017358865A1 (en) 2019-05-09
CA3043397A1 (en) 2018-05-17
JP2020504082A (ja) 2020-02-06
EP3538134B1 (en) 2021-12-29
CN110381986A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
EP3297656B1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
CN110381986B (zh) 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
AU2017358861B2 (en) Truncated von Willebrand Factor polypeptides for treating hemophilia
JP6651548B2 (ja) 改変フォン・ヴィルブランド因子を製造するための方法
KR20200018690A (ko) 절단된 vwf에 의한 fviii 면역원성의 조절
US20220348637A1 (en) Polypeptides for inducing tolerance to factor viii
HK40013462B (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
HK1250625B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359A (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359B (en) Truncated von willebrand factor polypeptides for treating hemophilia
KR20220029733A (ko) 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment